Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bone Biologics Corp
(NQ:
BBLG
)
1.120
-0.020 (-1.75%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bone Biologics Corp
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
October 21, 2024
From
Bone Biologics
Via
Business Wire
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
August 02, 2024
From
Bone Biologics Corporation
Via
Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
June 21, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
June 20, 2024
From
Bone Biologics Corporation
Via
Business Wire
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
June 18, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
June 17, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
Bone Biologics Announces Closing of $2.0 Million Public Offering
March 06, 2024
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Announces Pricing of $2.0 Million Public Offering
March 04, 2024
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Reports Progress With NB1 Clinical Program
March 01, 2024
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
January 11, 2024
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
January 10, 2024
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Announces 1-for-8 Reverse Stock Split
December 18, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 20, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 16, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
September 26, 2023
From
Bone Biologics
Via
Business Wire
BioMedNewsBreaks – Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering
June 21, 2023
Via
Investor Brand Network
Bone Biologics Prices $5.0 Million Underwritten Public Offering
June 14, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Effects 1-for-30 Reverse Stock Split
June 06, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
April 11, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
January 26, 2023
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics CEO Issues Letter to Stockholders
October 25, 2022
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
October 12, 2022
From
Bone Biologics Corporation
Via
Business Wire
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
October 07, 2022
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference
January 05, 2022
From
Bone Biologics Corporation
Via
Business Wire
Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
October 18, 2021
From
Bone Biologics Corp.
Via
Business Wire
Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
October 13, 2021
From
Bone Biologics Corp.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.